A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers

A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers

Objective: This study compared the pharmacokinetics (PK), safety, and immunogenicity of the biosimilar TAB008 monoclonal antibody to bevacizumab (Avastin®) in normal healthy Chinese male volunteers.Methods: In this randomized, double-blind, parallel controlled study, a total of 100 healthy Chinese m...

Full description

Bibliographic Details
Main Authors: Jin Wang, Lu Qi, Long Liu, Zejuan Wang, Gang Chen, Yu Wang, Xiaona Liu, Ying Liu, Huijuan Liu, Yuanxu Tong, Chen Liu, Chunpu Lei, Xinghe Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Pharmacology
Subjects:
TAB008 monoclonal antibody injection
Avastin®
pharmacokinetics
biosimilarity
immunogenicity
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00905/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.00905/full

Similar Items